Consultant

Ewa Budzynski, PhD, DABT

Dr. Ewa Budzynski is a Board certified-toxicologist with over 15 years of experience in drug development working in toxicology and pharmacology, supporting the development of small molecules, oligonucleotides, and biologics (including antibody drug conjugates, antibodies, cell and gene therapies). Most recently Ewa was a Project Toxicologist at PTC Therapeutics and Regenxbio where she was responsible for toxicology strategy development and execution and support of gene therapy product development ranging from discovery to late stage. She also supported process impurity risk assessment and was a Program Lead, responsible for leading the team towards candidate nomination.

Ewa received her PhD in Biomedical Engineering from Northwestern University in Retinal Metabolism and has since authored over 40 scientific articles published in peer reviewed journals, reviews, and/or conference abstracts. Following a postdoctoral fellowship in mammalian genetics, with concentration on retinal diseases, at Jackson Laboratory, Ewa moved to the drug development industry. She held pharmacology positions developing screening assays and animal disease models at Bausch & Lomb and Acucela. Ewa transitioned to toxicology over 10 years ago, joining Covance Laboratories (now LabCorp) as Study Director in the Ocular Safety Assessment Group. While at Covance Ewa supported the development of different products including devices, small molecules, oligonucleotides, and biologics (e.g., monoclonal antibodies, gene and cell therapy). Ewa is an active member of the American College of Toxicology (ACT) and Society of Toxicology (SOT).